EA201001028A1 - Суспензия, содержащая немикронизированные микрочастицы эзетимиба - Google Patents

Суспензия, содержащая немикронизированные микрочастицы эзетимиба

Info

Publication number
EA201001028A1
EA201001028A1 EA201001028A EA201001028A EA201001028A1 EA 201001028 A1 EA201001028 A1 EA 201001028A1 EA 201001028 A EA201001028 A EA 201001028A EA 201001028 A EA201001028 A EA 201001028A EA 201001028 A1 EA201001028 A1 EA 201001028A1
Authority
EA
Eurasian Patent Office
Prior art keywords
microparticles
ezetimibe
suspension
suspension containing
unimicronized
Prior art date
Application number
EA201001028A
Other languages
English (en)
Other versions
EA017941B1 (ru
Inventor
Примоз Бенкиц
Матей Смрколь
Ален Кльайиц
Грегор Седмак
Original Assignee
Крка, Товарна Здравил, Д.Д., Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201001028(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Крка, Товарна Здравил, Д.Д., Ново Место filed Critical Крка, Товарна Здравил, Д.Д., Ново Место
Publication of EA201001028A1 publication Critical patent/EA201001028A1/ru
Publication of EA017941B1 publication Critical patent/EA017941B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к суспензии, содержащей немикронизированные микрочастицы эзетимиба, имеющие малый размер частиц и высокую удельную площадь поверхности, где указанные микрочастицы эзетимиба получают без процесса микронизации и где этот способ предотвращает вторичную агломерацию микрочастиц эзетимиба в суспензии. Суспензию немикронизированных микрочастиц эзетимиба можно непосредственно использовать в способе получения фармацевтической композиции. Настоящее изобретение относится к немикронизированным микрочастицам эзетимиба, имеющим малый размер частиц и высокую удельную площадь поверхности, которые могут быть выделены из суспензии.
EA201001028A 2007-12-17 2008-12-17 Суспензия, содержащая микрочастицы эзетимиба EA017941B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200700331 2007-12-17
SI200800017 2008-01-24
PCT/EP2008/067808 WO2009077573A2 (en) 2007-12-17 2008-12-17 Suspension comprising non-micronized ezetimibe micro-particles

Publications (2)

Publication Number Publication Date
EA201001028A1 true EA201001028A1 (ru) 2010-12-30
EA017941B1 EA017941B1 (ru) 2013-04-30

Family

ID=40568477

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001028A EA017941B1 (ru) 2007-12-17 2008-12-17 Суспензия, содержащая микрочастицы эзетимиба

Country Status (5)

Country Link
EP (1) EP2231118B2 (ru)
CN (1) CN101938995A (ru)
AU (1) AU2008337435A1 (ru)
EA (1) EA017941B1 (ru)
WO (1) WO2009077573A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2965752T3 (pl) * 2007-12-10 2025-12-08 Assia Chemical Industries Ltd. Formulacja farmaceutyczna zawierająca ezetymib
WO2010113175A2 (en) 2009-04-01 2010-10-07 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
PT2459175T (pt) * 2009-07-28 2018-02-07 Egyt Gyogyszervegyeszeti Gyar Novo processo de granulação e o granulado assim preparado
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
WO2013066279A1 (en) * 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
CN103877051B (zh) * 2014-04-19 2015-09-30 青岛科技大学 一种依折麦布片的制备方法
EP3256546B1 (en) 2015-02-10 2019-08-14 Ciris Energy, Inc. Depolymerization process
CN105503686A (zh) * 2015-12-31 2016-04-20 安徽美诺华药物化学有限公司 一种依替米贝的合成方法
JP6711709B2 (ja) * 2016-05-10 2020-06-17 株式会社トクヤマ エゼチミブの製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2344127C2 (ru) * 2000-11-30 2009-01-20 Тева Фамэситикл Индастрис Лтд. Новые кристаллические структуры (полиморфные модификации) полукальциевой соли аторвастатина и способы получения этих и других полиморфных модификаций соли аторвастатина
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
RU2005136987A (ru) * 2003-04-29 2006-03-20 Акцо Нобель Н.В. (NL) Способы, включающие применение кристаллизации с антирастворителем
US20060160785A1 (en) * 2004-12-03 2006-07-20 Judith Aronhime Ezetimibe polymorphs
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe

Also Published As

Publication number Publication date
EA017941B1 (ru) 2013-04-30
EP2231118A2 (en) 2010-09-29
EP2231118B1 (en) 2013-12-04
AU2008337435A1 (en) 2009-06-25
WO2009077573A3 (en) 2010-03-18
CN101938995A (zh) 2011-01-05
EP2231118B2 (en) 2017-05-17
WO2009077573A2 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
EA201001028A1 (ru) Суспензия, содержащая немикронизированные микрочастицы эзетимиба
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
EA201171195A8 (ru) Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
EA201391318A1 (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
AU2016219704A1 (en) Anti-Notch1 antibodies
GEAP202114672A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
MX340055B (es) Metodos y composiciones de nanoparticulas sin priones.
WO2012165815A3 (ko) 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
AU2013311573A8 (en) Methods of treating Alzheimer's disease and pharmaceutical compositions thereof
WO2011082266A3 (en) Substituted heterocyclic compounds
EA201171435A1 (ru) Твердые фармацевтические композиции и способы их получения
EA200600323A1 (ru) γd-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
WO2010021717A3 (en) Hcv protease inhibitors
EA201390079A1 (ru) Пероральная лекарственная форма деферазирокса
NZ602578A (en) Polymorphic forms st-246 and methods of preparation
EA201300127A1 (ru) Комбинированная фармацевтическая композиция и способ лечения головокружения различного генеза, кинетоза и вегетососудистой дистонии
WO2008061108A3 (en) Phthalazine derivatives
JO2911B1 (en) Thiazoloperidine-2-amoxicillinyl-phenyl and thiazoloperazine-2-amoxicillinyl phenyl amine as agents for the control of leukotrien A4 hydrolase
UA107836C2 (ru) Метод лечения болезни альцгеймера
WO2014068586A3 (en) Solid oral compositions of tolvaptan
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
NZ730585A (en) Indolinone compounds and uses thereof
WO2011045760A3 (en) Micronized olmesartan medoxomil compositions
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201270377A1 (ru) Стабильные композиции sns-595 и способы их получения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU